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Abstract: Hemorrhagic fever with renal syndrome (HFRS) is endemic in Tatarstan, where thousands
of cases are registered annually. Puumala orthohantavirus is commonly detected in human case samples
as well as in captured bank voles, the rodent hosts. The pathogenesis of HFRS is still not well
described, although the cytokine storm hypothesis is largely accepted. In this study, we present
a comprehensive analysis of a fatal HFRS case compared with twenty four non-fatal cases where
activation of the humoral and cellular immune responses, pro-inflammatory cytokines and disturbed
blood coagulation were detected using immunological, histological, genetic and clinical approaches.
Multiple organ failure combined with disseminated intravascular coagulation syndrome and acute
renal failure was the cause of death. Decreased Interleukin (IL)-7 and increased IL-18, chemokine
(C-C motif) ligand (CCL)-5, stem cell growth factor (SCGF)-b and tumor necrosis factor-beta (TNF-β)
serum levels were found, supporting the cytokine storm hypothesis of hantavirus pathogenesis.
Keywords: HFRS; IL-18; CCL5; SCGF-b; TNF-β; cytokine; fatal case; Puumala orthohantavirus
1. Introduction
Hemorrhagic fever with renal syndrome (HFRS) is an acute zoonotic disease endemic in the
Republic of Tatarstan, Russia [1]. Puumala orthohantavirus (PUUV) is commonly isolated from human
HFRS blood and tissue samples as well as bank voles captured in the region [2]. HFRS is characterized
by kidney insufficiency and disturbed blood coagulation [3–7]. Acute kidney failure (AKF) and
disseminated intravascular coagulation (DIC) syndrome are recognized as the primary causes of
death [3,8]. Severe HFRS cases are however rare, with most patients presenting with the milder form
of the disease, often referred as nephropathia endemica (NE). NE is characterized by oliguria and
thrombocytopenia. The immune reaction to hantavirus infection is believed to be central in HFRS
pathogenesis; however, little is known about the mechanisms of hantavirus induced death. This
knowledge gap limits the development of effective therapeutics to reduce mortality.
Viruses 2019, 11, 601; doi:10.3390/v11070601 www.mdpi.com/journal/viruses
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2. Materials and Methods
2.1. Subjects
Serum samples from 24 subjects (20 male and 4 female; 44.5 ± 1.8 years) non-fatal and one fatal
case (male, 58 years old) admitted to the Agafonov Republican Clinical Hospital for Infectious Disease,
Republic of Tatarstan, between Spring 2015 and Fall 2016 were used in the study. Twenty four serum
samples were obtained from the early stages (3.6 ± 0.3 days) and eighteen samples from the late stages
(10.5 ± 0.8 days) of non-fatal HFRS. Samples from fatal HFRS were collected once, on day seven after
admission to the hospital. Diagnosis of HFRS was established based on clinical presentation and was
serologically confirmed by detection of anti-hantavirus antibodies. Samples were collected following
the standard operation procedure protocol for diagnosis of hantavirus infection. Serum samples from
27 controls without HFRS (21 male and 6 female; 40.8 ± 7.4 year age) were also collected.
2.2. Ethics Statement
The Ethics Committee of the Kazan Federal University approved this study, and signed informed
consent was obtained from each patient and controls according to the guidelines approved under this
protocol (article 20, Federal Law “Protection of Health Right of Citizens of Russian Federation” N323-
FZ, 11.21.2011). Informed consent was collected from the next of kin to the fatal HFRS patient.
2.3. Animal Samples
Frozen rodent lung tissue samples and information about trapping localities were obtained from
the Federal Healthcare Institution “Center for Hygiene and Epidemiology of the Republic of Tatarstan
(Tatarstan)”. Rodents were trapped by the village of Vasilevo, the Republic of Tatarstan in May and
September 2016.
2.4. Cell Lines and Cell Culture
HEK293FT and Vero E6 cells were obtained from ATCC (American type culture collection,
Manassas, VA, USA) and maintained in Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) (PanEco, Moscow, Russia)), 2 mM L-glutamine, 25 U/mL penicillin,
and 25 µg/mL streptomycin (PanEco, Moscow, Russia).
2.5. Cloning and Expression of PUUV Glycoproteins
pWPT-PUUM plasmid containing the PUUV glycoprotein coding ORF was purchased from
GenScript (Piscataway, NJ, USA). HEK293FT cell monolayers were transfected with the mix of three
plasmids: pWPT-PUUMV (vector plasmid), psPAX2 (#12260, Addgene, Watertown, MA, USA) as
a packaging plasmid and pCMV-VSV-G (#8454, Addgene, Watertown, MA, USA) as an envelope
plasmid. Sixteen hours after transfection, fresh medium was added and supernatant containing the
PUUV glycoprotein expressing lentivirus (LV-PuuM) was collected at 98 h. The virus was concentrated
by ultracentrifugation (26000 rpm, 4 ◦C, 2 h) and stored at −80 ◦C.
2.6. Lentivirus Titer
HEK293FT cells were transduced with serial dilutions of LV-PuuM (10−1–10−9). Forty eight
hours later, cells were trypsinized, washed with PBS (pH 7.4), and incubated with mouse monoclonal
anti hantavirus glycoprotein antibodies (1:100 dilution, Abcam, Cambridge, MA, USA) for 2 h at
room temperature. Washed (3×, pH 7.4 PBS) cells were incubated with donkey anti-mouse IgG
Alexa 647 antibodies (1:1000, Invitrogen, Waltham, MA, USA) for 1 h at room temperature. Washed
(3× pH7.4 PBS) cells were fixed (CellFix; BD Biosciences, San Jose, CA, USA) and analyzed for any
PUUV glycoproteins expression using BD FACS AriaIII equipment (BD Biosciences, San Jose, CA, USA).
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The transduction coefficient (%) is expressed as the ratio of infected cells to the total number of
cells in 1 mL. Transduction unit (TU) was calculated as:
TU/mL = number of seeded cells × dilution factor × transduction coefficient (%)/volume of added
viral stock.
2.7. Hantavirus ELISA
The Hantagnost diagnostic ELISA kit (Institute of Poliomyelitis and Viral Encephalitis, Moscow,
Russia) was used to determine the hantavirus-specific antibody titers.
2.8. RNA Extraction and RT-PCR
Total RNA was extracted (100 µL of serum, 50 µg tissue, 105 leukocytes) using TrIzol® reagent (Life
Technologies, Carlsbad, CA, USA). cDNA was generated using the Super Script kit (Life Technologies,
Carlsbad, CA, USA) according to the manufacturer’s instructions. Single round and nested PCR was
used to amplify PUUV products in animal and human samples, respectively. Nested PCR products
were sequenced using ABI PRISM 310 and Big Dye Terminator 3.1 Sequencing Kit (ABI, Waltham, MA,
USA)) to confirm the hantavirus strain.
2.9. Quantitative PCR (qPCR)
An aliquot of total RNA (40 ng) was used to synthesize the cDNA (Superscript Kit; Invitrogen,
Waltham, MA, USA). cDNA (1 µL) was used for the relative quantification of transcripts in a qPCR
assay (ThermoFisher, Waltham, MA, USA). Relative values were calculated by normalizing qPCR data
to the respective values for glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The fold changes
were calculated by ∆∆Ct method by taking the corresponding control group as reference. All qPCR
reactions were performed at least in duplicates and repeated three times.. Primer sequences (Evrogen,
Moscow, Russia) and expected PCR product sizes are summarized in Table 1.
Table 1. Primers used in the study.
Name of the Primer Nucleotide Sequence PCR Product Size
RT-PCR
PuuV-For 1st round 5′-CTGCAAGCCAGGCAACAAACAGTGTCAGCA-3′ 723 bp
PuuV-Rev 1st round 5′-GTCTGCCACATGATTTTTGTCAAGCACATC-3′
PuuV-For 2st round 5’-AAGTGGCCAGACAGCAGATT-3’ 217 bp
PuuV-Rev 2st round 5’-GGCAGTAGGCATGGAAACAT-3’
qPCR
PuuVN-F 5′-AGGCAACAAACAGTGTCAGC-3′ 186 bp
PuuVN-R 5′-AATCCCAGTCGGGTCAGTAG-3′
GAPDH-F 5′-TTTGGCTACAGCAACAGG-3′ 107 bp
GAPDH-R 5′-GGTCTCTCTCTTCCTCTTG-3′
2.10. DNA Extraction and PCR
DNA was extracted from human blood (100 µL) and cheek swabs using DNA/RNA Extraction Kit
(Litekh, Moscow, Russia). The CCR5 genotype was determined by PCR using primers [9] spanning
over the exon 4 region of the CCR5 gene. Amplification products were separated by gel electrophoresis.
2.11. Multiplex Analysis
Serum levels of 94 analytes were analyzed using Bio-Plex (Bio-Rad, Hercules, CA, USA) multiplex
magnetic bead-based antibody detection kits following manufacturer’s instructions. Multiplex kits,
Bio Plex Pro Human Cytokine 21-plex and Bio Plex Human Cytokine 27-plex panels were used in the
study. Data collected was analyzed using with MasterPlex CT control software and MasterPlex QT
analysis software (MiraiBio, Alameda, CA, USA).
Viruses 2019, 11, 601 4 of 20
2.12. Hantavirus Antibody Epitope Analysis
Hantavirus nucleocapsid and glycoprotein overlapping (15 aa) peptide library was purchased
from GeneScript (Piscataway, NJ, USA). Peptide (1 µg/well) was added into the well (96 well plate, HB;
Immulon, SPL Lifesciences, Pocheon, Korea) and incubated overnight at 4 ◦C. Wells were the washed
(3×; PBS, 0.1% Tween-20 (PBS-T)), and blocked (2% bovine serum albumin (BSA); Carbonate-Bicarbonate
Buffer, pH 9.0) for 1 h at 37 ◦C and washed again (3 × PBS, 0.1% Tween-20). Serum samples (50 µL)
were diluted in PBS-T containing 0.5% BSA, added into the wells in duplicate and incubated overnight
at 4 ◦C. Washed (3× PBS-T), antigen-antibody complexes were incubated with Horseradish Peroxidase
(HRP) conjugated goat anti-human IgG antibody (1: 20000; Novex® Cat. No. A24470, (Waltham, MA,
USA)) and incubated for 2 hours at 37 ◦C. At the end of incubation, wells were washed (3× PBS-T) and
incubated with 3,3’,5,5’-tetramethylbenzidin (Hema-medica, Moscow, Russia) for 15 min in the dark.
Phosphoric acid was added and changes in color were visualized using a spectrophotometer, Tecan
Infinite Pro (TECAN, Männedorf, Switzerland).
2.13. Neutralizing Antibody Titer
Serial dilutions of serum samples were mixed with lentivirus expressing PUUV glycoproteins
(1 × 105 transducing units (TU)/mL) and incubated for 1 h at 37 ◦C. Vero E6 monolayers (96 well plate;
(Corning, Corning, NY, USA)) were inoculated with antibody-antigen mix for 1 h (37 ◦C, 5% CO2),
washed with PBS and fresh medium (DMEM, 10% FBS, 2 mM L-glutamine, 25 U/mL penicillin, and
25 µg/mL streptomycin) was added. Five days later cells were fixed and PUUV envelope proteins were
probed using mouse anti-Hantavirus glycoprotein G2 antibody (1:100, Abcam, Cambridge, MA, USA)
followed by goat anti-mouse Alexafluor 647 (Invitrogen, Waltham, MA, USA). PUUV glycoprotein
was detected using a laser confocal microscope LSM800 (Carl Zeiss, Oberkochen, Germany). The
fluorescence intensity was analyzed using Image J software (NIH, Bethesda, MD, USA). Neutralizing
antibody titer was determined as the reciprocal of the serum dilution which decreased the fluorescence
intensity by 50% as compared to that in virus controls (without HFRS serum). A total of 6 fields were
counted in each sample.
2.14. Leukocyte Population Analysis
Blood sample (200 µL) was collected in ethylenediaminetetracetic acid (EDTA) tubes and used
for analysis. Thirteen non-fatal HFRS and twenty seven control blood samples were available for
this study. Leukocyte populations were analyzed using anti-human CD3-FITC (cat. 2324020 (Sony
Biotechnology, San Jose, CA, USA)), CD4-APC (cat. 2323070 (Sony Biotechnology, San Jose, CA, USA)),
CD8-PE (cat. 2322530 (Sony Biotechnology, San Jose, CA, USA)), CD14-Cy7 (cat. 367108 (Biolegend,
San Diego, CA, USA)) and CD20-Brilliant Violet421TM antibodies (cat. 302330 (Biolegend, San Diego,
CA, USA)). Blood (100 µL) was incubated with anti CD3+CD4+, CD3+CD8+, CD14+ and CD20+, and
was analyzed using a BD FACSAria III (BD Biosciences, San Jose, CA, USA). Data was processed with
the FlowJo software package (FlowJo LLC, Ashland, OR, USA).
2.15. Immunohistochemistry and Immunofluorescent Analysis
Post mortem tissue samples from the lung, kidney, brain, spleen, liver, heart and intestine were
collected and fixed in 4% paraformaldehyde for 4 h at 4 ◦C and cryoprotected with a 30% sucrose
solution in PBS. Tissue slides (0.5-µm) were deparaffinized with xylene and rehydrated through a
graded alcohol series. Antigen was retrieved using sodium citrate (0.01 M, pH 6.0) at 95 ◦C for 10 min,
rinsed in PBS and incubated in cold methanol for 20 min at –20 ◦C. Tissue sections were then incubated
with serum (matching the host of the secondary antibody) to block non-specific staining (1 h at 37 ◦C)
and incubated with the primary antibody overnight at 4 ◦C in a humidified chamber. After washing
3 times with PBS-T, the sections were incubated with the secondary antibody for 1 h at 37 ◦C. Slides
Viruses 2019, 11, 601 5 of 20
were examined using a Zeiss LSM 7000 scanning laser confocal microscope (Carl Zeiss Microscopy,
Thornwood, NY, USA) and images were captured with the Zeiss Zen 2009 analysis software.
Tissue morphology was analyzed by light microscopy using eosin-hematoxylin staining.
2.16. Phylogenetic Analysis
The nucleotide alignment and phylogenetic analysis of PUUV strains was based on partial S
segment sequences of 217 nucleotides in length (nucleotides 378–594). Phylogenetic analysis was
done using the MegAlign program (Clustal W algorithm), DNASTAR software package Lasergene v.
7.1.0.44 (DNASTAR, Madison, WI, USA) and MEGA v6.0 [10]. Parameters were adjusted manually.
Phylogenetic trees were constructed using Maximum Parsimony method included in Mega v6.0 [10].
For phylogenetic analysis we used PUUV partial S segment sequences from
the Republic of Tatarstan submitted to the GenBank: PUUV/Laishevo/MG_047/2015,
MG573266; PUUV/Teteevo/MG_165/2015, MG573272; PUUV/Vasilyevo/MG_130/2015, MG573296;
PUUV/Yash-Ketch/MG_338/2015, MG573279; PUUV/Vysokaya Gora/MG_064/2015, MG573275;
PUUV/Yash-Ketch/MG_054/2015, MG573297. Also, several partial S segment sequences of
the genetically distinct PUUV strains were downloaded from GenBank database (NCBI)
including: Samara_49/CG/2005, AB433843; Puu/Kazan, Z84204; PUUV Udmurtia/894Cg/91, Z21497;
CG17/Baskiria-2001, AF442613; Sotkamo 2009, HE801633; PUUV/Konnevesi/Mg_O22B/2005, JQ319168;
Kuchuk170/Mg/2007, KJ292966; CRF366, AF367071. Tula virus strain Sennickerode Sen05/205, EU439951
was used as an outgroup.
2.17. Statistical Analysis
Statistical analyses were conducted using R language for statistical computing [11], RStudio [12,13]
and package “tableone” [9]. Continuous variables were presented with their respective median (M),
first (Q1) and third (Q3) quartiles. Categorical variables were presented with cross-tables. Comparisons
were carried out using Mann–Whitney test for continuous and Fisher’s exact test for categorical
variables. The threshold used for statistical significance was p < 0.05.
Statistical analyses were performed using Prism 6.0 software (Graphpad, San Diego, CA, USA)
and the p-values were calculated using two-tailed t-tests. Significance was established at a value of
p < 0.05. Data are presented as mean ± SE.
3. Results
3.1. Clinical Summary
3.1.1. Presentation
Patient M, (58 years old, male) from Vasilevo, Tatarstan, was hospitalized with a two day history
of weakness, headache and high fever (39 ◦C) which progressed to vomiting with “coffee grounds”
consistency and loss of consciousness. On admission the patient was non-responsive, with pale
cyanotic skin and did not have a detectable pulse or arterial blood pressure. The patient had a previous
history of hypertension and had been prescribed enalapril (10 mg/day) and aspirin (100 mg/day).
3.1.2. Clinical Testing
Upon admission, hematology analysis revealed leukocytosis, severe thrombocytopenia and
decreased prothrombin index (PTI) (Table 2). Coagulopathy was also evident, with high levels of
fibrin D dimers and increased activated partial thromboplastin time (aPTT). Increased AST and ALT
indicating liver and tissue damage were present on admission. Failing kidney function was also
evident with increased creatinine and urea serum levels, as well as protein and red blood cells (RBC) in
the urine. Urine output was 700 mL/day. Esophagogastroduodenoscopy (EPGDS) revealed gastric and
duodenal bleeding. A CT scan demonstrated subarachnoid bleeding. Antibodies to hantavirus (IgG
and IgM) were detected.
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Table 2. Clinical laboratory data dynamics.
Day-Post Admission 0 2 4 7 9 11 12 14 15
Normal
Values
AP (mm/Hg) 90/50 100/60 120/80 115/70 110/70 114/70 100/75 90/60
Blood test
Leukocyte
(109 cell/L) 3.5–11.0 14.74 18.48 13.6 16.67 8.9 7.3 4.9 4.5
Hemoglobin (g/L) 130–170 140 137 95 103 101 82 78 91
Erythrocyte
(1012 cell/L) 4.2–6.9 4.91 4.87 3.2 3.42 3.49 2.95 2.79 3.2
Hematocrit 39–62 39.6 38.4 27 29.13 31 25.7 24.3 28.3
Thrombocyte
(109 cells/L) 140–450 5 3 39 65 21 49 38 53
Arterial Blood Gas test
pH 7.45 7.07 7.47 7.44 7.43 7.4 7.2
P CO2 (mmHg) 33–45 24.5 28.9 35.4 40.6 32.3 52.1
P O2 (mmHg) 75–100 45.5 46.6 41.8 41.2 65.4
HCO3- (mEq/L) 21–28 13.3 20,6 23.6 29.1 24.8
BE -8.8 -2.6 -1 1,6 -2.4
02 SAT (%) 94–100 74.7 81 89
Biochemical analysis
K+ (mM/L) 3.5–5.0 4.9 4.0 4.3 4.3 6.6 5.4 5.1 7.3
Na+ (mM/L) 135–145 141 143 146 141 140 144 142 141
Cl- (mM/L) 95–105 92 95 99 96 90 95
Bilirubin (µM/L) 2–25 20 47.1 49 54.9
Bilirubin, direct (µM/L) 0–9 9 7
PTI (%) 72–123 55 69 60 78
PTI by Quick (%) 78–142 49.8 61 66.3
Fibrinogen B (mg/dL) 1.7–4.2 1.9 2.5 1.8 3.3 6
Spontaneous fibrinolysis (%) 10–20 >50 >40 >45 >40 >40 >40 >40
Soluble fibrinomonomeric
complexes (SFMC) (U) 0.36–0.48 5.5 4.5 6.5 4
Activated partial
thromboplastin time (aPTT) (s) 30–40 51 29 38.2 43 40 39.8
Antithrombin (AT) lll (%) 76–126 86.6% 56%
International normalised ratio
(INR) 0.82–1.18 1.7 1.54 1.69 1.2 1.2 1.2 1.46 1.37
D dimer (ng/µL) + +
++
+ + +
Procalcitonin (ng/mL) 0–0.15 12.8 12.8 >12.8
C-reactive protein (CRP)
(mg/L) 0–6 48 96
Amylase (U/L) 25–190 140 600 852
Alanine aminotransferase
(ALT) (U/L) 5–56 510 1211 1250 389 98 21
Aspartate transaminase (AST)
(U/L) 8–40 738 2316 2400 500 136 40
Lactate dehydrogenase (LDH)
(U/L) 140–280 3328
Creatinine (µM/L) 60–118 286 547 949
Urea (mM/L) 3–7 14 19.9 43 29 50 65 56
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Table 2. Cont.
Day-Post Admission 0 2 4 7 9 11 12 14 15
Urinalysis
Protein (g/L) absent 0.15 0.9 4 4 1.54
Red Blood Cells (RBC)
(cells/field) 0–3 10–20 4–5 many many many
3.1.3. Treatment
Multiple transfusions of cryopreserved plasma and thrombocytes were performed increasing
thrombocyte count and blood pressure. However, the patient’s condition deteriorated further with
progressive multiple organ failure. Oliguria developed with urine output decreased to 50 mL per day.
This progressed to anuria by day three after the disease onset.
Due to progressing respiratory failure the patient was intubated and BIPAP (Biphasic Positive
Airway Pressure) artificial ventilation was initiated. A medically induced coma was initiated (Atropini
0.1% (0.5 mL) i.v, Promedoli 2% (1.0 i.v); induction with i.v. Natrii oxybutyratis 20% (25.0 mL);
myorelaxation with Listenoni 100 mg; continues support with bolus injections of Emulsi Propofol
100 mg). Despite the therapy instituted the thrombocyte count remained low and the patient’s blood
pressure further declined. The patient’s cardiac function was supported by an infusion of dopamine
(5 µg/kg/min, (350 µg/min); heart sounds were faint. By day 3 the patient’s blood pressure (BP) was
100/65 mmHg, pulse 90 beat/min, temperature 36.7 ◦C, oxygen saturation was 69%. The patient’s neck
muscles were rigid and the skin was pale with multiple hemorrhages. The abdomen was bloated and
painful with absent peristalsis. EPGDS at this stage did not show evidence of bleeding. A cerebro-spinal
fluid (CSF) sample was taken with analysis demonstrating proteins (2.01 g/L), leukocytosis (39 cells/µL)
and a large number of erythrocytes.
The patient’s condition worsened progressively, leading to coma by the evening on day 3 with
increasing skin hemorrhages and multiple nasal bleeds that could not be controlled. Hemodialysis was
initiated on day 6 with a tracheostomy tube placed for continuing ventilation. Ascites developed on day
11 with 800 mL of fluid drained from the abdomen. By day 13 fibro-bronchoscopy revealed bronchial
and pulmonary bleeding. Bleeding was also detected at the site of the peritoneal drainage. Multi-slice
computer tomography (CT) revealed multiple ground-glass shadows in the posterior side of both
lungs and lateral side of the right lung (Figure 1), indicating pulmonary effusion. Enlarged thoracic
lymph nodes were also detected. Sixteen days after admission the patient developed progressive
cardio-vascular insufficiency and failure, DIC syndrome, and multi organ failure. Resuscitation was
unsuccessful and the patient was pronounced dead.
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CT scanning demonstrates multiple small flakes of ground-glass shadows in the back of both
lungs. Also, the shadow is found on the lateral side of the right lung. Enlarged lymph nodes are
also detected.
3.1.4. Clinical Diagnosis
Hemorrhagic Fever with Renal Syndrome (HFRS) severe form complicated with acute renal
failure (grade 3), DIC syndrome (stage 3), and systemic multiorgan insufficiency (pulmonary, renal
and cardiac). Polysegmental pneumonia, severe form (respiratory insufficiency 3 stage, extracorporeal
ventilation). Coma stage 1.
A post mortem examination demonstrated hemorrhagic syndrome, pulmonary and
tracheobronchial bleeding, blood aspiration, hepatic bleeding. The overall clinical syndrome was
consistent with HFRS with acute renal failure, DIC and multiorgan failure.
3.2. Laboratory Analysis (Table 2)
Serial blood biochemistry and hematology analyses using hematology analyzer (Advia 2120i
(Simens, Munich, Germany) during the patient’s illness revealed severely impaired kidney function
and blood coagulation. Progressively increasing serum levels of creatinine and urea, determined using
biochemical analyzer (Architect c8000 (Abbott, Abbott Park, IL, USA) indicate that the function of the
kidney was progressively deteriorating. Additionally, the presence of protein and erythrocytes in the
urine suggested damage to the glomerulus and filtration membrane of the nephrons.
Decreased erythrocyte counts and hemoglobin levels (Table 2) were consistent with on-going
bleeding. Additionally, drastically decreased thrombocyte counts (Table 2), which were not restored by
therapeutic intervention, was considered one of the major causes of the DIC syndrome that developed
in this patient. DIC syndrome was also confirmed by increased PTI, fibrinogen level, spontaneous
fibrinolysis and the presence of fibrinogen D dimers (Table 2). Despite the intensive care measures, the
patient’s blood pressure was not restored. Multiple organ damage was indicated by high serum levels
of bilirubin, amylase, ALT, AST, creatinine and urea (Table 2).
3.2.1. Circulating Leukocyte Analysis
Leukocyte populations, CD3+ CD4+ (CD4 T cells), CD3+ CD8+ (CD8 T cells), CD14+ (monocytes)
and CD20+ (B cells), were analyzed in the blood of this fatal HFRS patient and 13 non-fatal HFRS
using BD FACSAria III (BD Biosciences, San Jose, CA, USA). Data was processed with FlowJo software
package (FlowJo LLC, Ashland, OR, USA) (Table 3). Leukocyte populations did not differ significantly
between this fatal and the non-fatal HFRS cases; however, there were markedly higher T cell and B cell
counts and lower monocyte counts in the fatal case than the non-fatal cases.
Table 3. Circulating leukocyte populations in fatal and non-fatal HFRS.
CD3+CD4+ (%) CD3+CD8+ (%) CD14+ (%) CD20+ (%)
Fatal 6 11 0.7 5.2
Non-fatal 3.13 ± 3.78 6.05 ± 4.12 3.03 ± 1.66 3.33 ± 1.57
Data are presented as mean ± SE. Significance was established at a value of p < 0.05.
3.2.2. Antibody Response
Serum IgM and IgG antibodies to hantavirus antigens were determined using the Hantagnost
commercial diagnostic ELISA according to manufacturer’s instructions (Vektor-best, Novosibirsk,
Russia). The titer of hantavirus specific IgM and IgG was 1:600 and 1:400, respectively, suggesting recent
hantavirus exposure. Interestingly, IgM and IgG titers were higher in non-fatal HFRS, 1:2260 ± 947.8
and 1:5600 ± 2653.3, respectively. Analysis of hantavirus nucleocapsid antibody epitopes was done
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using panels of overlapping 15aa peptides (GeneScript, Piscataway, NJ, USA). Interestingly, the serum
from the fatal case was lacking in reactivity with any of viral nucleocapsid peptides in contrast to
serum from non-fatal HFRS, which reacted with multiple peptides from the PUUV N protein. Since
the fatal HFRS serum did react with the whole virus PUUV proteins used in Hantagnost, it could be
suggested that the epitopes recognized by this patient are conformational only.
Neutralizing antibodies play an important role in protection against hantavirus infection [14].
Therefore, we sought to determine the serum level of PUUV neutralizing antibodies in this fatal case
as compared to the non-fatal HFRS cases (Figure 2). Neutralizing antibody titer was determined as
the reciprocal of the serum dilution which decreased the fluorescence intensity by 50% as compared
to that in the lentivirus control (with no hantavirus protein). A total of 6 fields were counted in each
sample. Neutralizing antibody titer in the non-fatal HFRS cases varied from 100 to 320 however, the
titer of neutralizing antibodies in the fatal HFRS was 20, which was much lower than that of the
non-fatal cases.
The defect in humoral response was evident in this fatal HFRS case. Similar data was presented
by McNeil et al., demonstrating lack of hantavirus specific IgG in many fatal hantavirus pulmonary
syndrome (HPS) cases, while all non-fatal cases had detectable level of antibodies [15] Also, a lower
titer of neutralizing antibodies in severe hantavirus infection was demonstrated by Bharadwaj et
al. [16]. In another report, low anti-PUUV antibodies were shown to be associated with severe forms of
infection [17]. These authors suggested that passive immunotherapy could be beneficial for severe
PUUV infection. This assumption is also supported by our observation, demonstrating a lack of
hantavirus specific antibodies in fatal HFRS.
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Figure 2. PUUV neutralizing antibodies in the fatal and non-fatal HFRS sera. Blue – non-fatal HFRS;
red – fatal HFRS.
3.2.3. PUUV RNA
A PUUV strain (Figure 3), clustering together with isolates from different regions of Russia, was
detected in the blood sample from the fatal case. Phylogenetic analysis revealed that this PUUV was
closely related to the strains isolated from Finland (Finnish group).
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3.2.4. Immunohistochemistry and Immunofluorescent Analysis
Post mortem tissue samples from the lung, kidney, brain, spleen, liver, heart and intestine were
collected and used for histology and immunohistochemistry analysis. The most significant changes in
tissue structures and leukocyte infiltration were detected in the lungs (Figure 4) and kidney (Figure 5).
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Figure 4. Histochemistry and immunofluorescence analysis of the lung tissue from fatal HFRS.
Lung tissues (0.5–3-µm thick) were deparaffinized before histochemistry and immunofluorescence
analysis. A and B. Tissue samples were stained with hematoxylin and eosin (H&E). Arrow points at
exudate in the lung alveolus and bronchiole. C. hantavirus nucleocapsid protein (1:100, Santa Cruz
Biotechnology, Dallas, TX, USA) and anti-mouse Alexa 488 (1:1000; Invitrogen, Waltham, MA, USA);
D. CD4+ leukocytes (polyclonal anti-CD4 (1:100, Abcam, Cambridge, MA, USA) and anti-rabbit
Alexa647 (1:1000; Invitrogen, Waltham, MA, USA); E. CD20+ leukocytes (monoclonal anti-CD20 (1:50,
Abcam, Cambridge, MA, USA) and anti-mouse Alexa 488 (1:1000; Invitrogen, Waltham, MA, USA);
DAPI – used to visualize nucleus. White arrows show positive CD20+ infiltrating leukocytes.
Viruses 2019, 11, 601 12 of 20
Viruses 2019, 11, x FOR PEER REVIEW 12 of 20 
 
 
Figure 5. Histochemistry and immunofluorescence analysis of kidney from fatal HFRS. Kidney tissues 
(0.5–3-μm thick) were deparaffinized before histochemistry and immunofluorescence analysis. A and 
B. Tissue samples were stained with hematoxylin and eosin (H&E). Arrows in the figure show whit 
changes in kidney structure. White arrows - kidney glomeruli exhibited wrinkling epithelium. Black 
arrows mark the plasmorrhexis of kidney. C. hantavirus nucleocapsid protein (1:100, Santa Cruz 
Figure 5. Histochemistry and immunofluorescence analysis of kidney from fatal HFRS. Kidney tissues
(0.5–3-µm thick) were deparaffinized before histochemistry and immunofluorescence analysis. A and
B. Tissue samples were stained with hematoxylin and eosin (H&E). Arrows in the figure show whit
changes in kidney structure. White arrows—kidney glomeruli exhibited wrinkling epithelium. Black
arrows mark the plasmorrhexis of kidney. C. hantavirus nucleocapsid protein (1:100, Santa Cruz
Biotechnology, Dallas, TX, USA) and anti-mouse Alexa 488 (1:1000; Invitrogen, Waltham, MA, USA).
D. CD4+ (1:100, Abcam, UK) and anti-rabbit Alexa 647 (1:1000; Invitrogen, Waltham, MA, USA).
E. CD8+ (1:100, Abcam, UK) and anti-mouse Alexa 647 (1:1000; Invitrogen, Waltham, MA, USA)
F. clusterin (1:100, Santa Cruz Biotechnology, Dallas, TX, USA) and anti-mouse Alexa 647 (1:1000;
Invitrogen, Waltham, MA, USA). DAPI was used to visualize the nucleus.
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The lung structures were severely damaged, and destruction of the alveoli was detected (Figure 4A).
Also, exudate was found in the alveoli as well as thickened alveoli walls. Hemostasis was evident in the
blood vessels. Additionally, mucus and blood were detected inside of bronchioles (Figure 4B). These
findings are consistent with the diagnosis of pneumonia based on spiral computer tomography findings.
Immunofluorescent analysis demonstrated hantavirus antigens in the lung (Figure 4C). Moderate
leukocyte infiltration containing CD4+ and CD20+ lymphocytes, is detected (Figure 4D and E).
Glomerular and tubular damage was detected in kidney tissue (Figure 5A,B). Kidney glomeruli
were shrunk which could be explained by the previous history of long lasting hypertension (Figure 5A).
Additionally, tubular epithelial cells were flattened with plasmorrhexis (Figure 5B). Some cells presented
with karyorrhexis. Hantavirus antigens were detected in tubular epithelial cells (Figure 5C). CD4+,
CD8+ and CD20+ lymphocyte infiltration was detected in kidney tissue (Figure 5D, E and F). Also,
clusterin expression (which has been previously associated with HFRS) [1,18] was demonstrated
at the basal side of the tubular epithelial cells (Figure 5G). Immunofluorescent analysis revealed
that infiltrating leukocytes were CD4+, CD8+ and CD20+, suggesting that lymphocytes (T-helpers,
cytotoxic T cells (CTL) and B cells) are primarily migrating across the endothelium.
PUUV RNA was detected in circulating CD8+ and CD14+ leukocytes using qPCR. In contrast,
viral genome was not detected in CD4+ and CD20+ lymphocytes (Table 4).
Table 4. PUUV RNA detection in various leukocyte populations.
Leukocyte Populations Fold Changes, p < 0.05
CD4+ 0.94 ± 0.02
CD8+ 28.98 ± 0.02
CD14+ 25.11 ± 2.0
CD20+ 0.86 ± 0.11
Leukocyte populations were separated using BD FACSAria III and used for RNA extraction
(purity of leukocyte populations was 94.3% ±2.6%). PUUV RNA was detected by qPCR. Relative
values were calculated by normalizing qPCR data to the respective GAPDH. The fold changes were
calculated by ∆∆Ct method by taking the corresponding control group as reference. Data are presented
as mean ± SE. Significance was established at a value of p < 0.05.
3.2.5. Serum Cytokines
Serum from the terminal case was collected on the 7th day after hospitalization and used to
identify cytokines linked to the HFRS lethal outcome (Table 5). Analytes in serum from 24 early
(3.6 ± 0.3 days) and 18 late (10.5 ± 0.8 days) cases of non-fatal HFRS were compared to those in the
fatal case. First, cytokines for which the level in the fatal case was outside the range found in early and
late HFRS were identified. Next, the coefficient of difference (CD) was determined by dividing the
cytokine value in the fatal case by the value of the 99% confidence interval for the same cytokine in
non-fatal early or late HFRS patients. A CD higher or lower than 2.0 was considered as significant.
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Table 5. Serum urea, creatinine and cytokine levels in fatal and non-fatal (early and late) HFRS.
Analyte Fatal
(pg/mL)
Late HFRS Early HFRS
pg/mL Fold Change pg/mL FoldChange
Urea 14.00 4.00 [2.50; 6.3] 2.22 7.00 [0; 38.00]
Creatinine 286.00 112.00 [77.00; 142] 2.01 131.00 [18.00; 545.00]
Interferon alpha-2
(IFN-2a) 53.95 19.50 [10.90; 125.03] 21.24 [2.24; 129.35]
Interferon gamma
(IFN-γ) 41.69 6.26 [3.38; 95.52] 1.25 57.78 [5.73; 1026.17] 1.25
IL-1a 6.26 0.14 [0.02; 5.00] 0.14 [0.00; 5.00]
IL-1b 5.67 2.52 [0.99; 149.36] 2.10 [0.22; 308.78]
IL-1ra 149.90 91.69 [3.85; 1489.14] 76.92 [3.72; 3175.21]
IL-2Ra 195.57 36.76 [3.00; 4745.66] 0.04 84.29 [3.00; 4745.66]
IL-2 10.98 7.25 [2.50; 33.40] 5.57 [0.25; 241.84]
IL-3 203.16 59.27 [5.00; 376.26] 88.18 [5.00; 2806.74]
IL-4 26.58 4.45 [1.45; 14.37] 1.85 3.38 [0.02; 29.77] 0.89
IL-5 4.05 5.10 [0.43; 59.73] 4.64 [0.19; 29.57]
IL-6 18.73 16.45 [1.04; 15099.02] 9.82 [0.83; 15099.02]
IL-7 0.20 9.05 [2.33; 26.61] −11.65 5.75 [0.18; 96.86]
IL-8 95.57 32.00 [11.00; 266.19] 44.00 [3.00; 1058.80]
IL-9 9.43 37.49 [4.62; 318.27] 33.33 [1.36; 213.48]
IL-10 31.62 25.37 [8.61; 460.05] 17.48 [1.73; 832.71]
IL-12(p40) 1045.95 78.73 [9.00; 1207.96] 0.87 165.15 [1.70; 4220.54] 0.25
IL-13 21.51 4.77 [0.83; 14.76] 1.46 4.57 [0.02; 68.04]
IL-15 81.59 21.51 [3.52; 54.74] 1.49 16.38 [1.20; 143.74] 0.57
IL-16 898.02 151.19 [5.00; 658.51] 1.36 174.41 [5.00; 3330.59] 0.27
IL-17 79.91 21.13 [2.05; 91.25] 9.95 [0.53; 220.06]
IL-18 351.23 11.23 [0.99; 99.78] 3.52 14.53 [0.07; 137.16] 2.56
IL-22 17.52 6.80 [4.80; 45.00] 6.00 [2.00; 65.00]
CCL2 104.89 33.25 [3.91; 310.57] 30.00 [3.27; 2958.67]
CCL3 4.34 3.12 [0.56; 51.98] 2.15 [0.09; 51.98]
CCL4 111.92 70.88 [13.58; 897.03] 46.62 [4.50; 897.03]
CCL5 21833.09 133.00 [12.00; 7120.00] 3.07 124.98 [1.02; 8354.01] 2.61
CCL7 49.54 8.30 [1.35; 45.77] 1.08 13.56 [0.87; 327.46]
CCL11 65.05 69.12 [6.27; 496.41] 39.73 [2.78; 666.70]
CCL27 155.80 45.37 [4.00; 200.06] 0.78 47.10 [0.04; 200.06] 0.78
Chemokine (C-X-C
motif) ligand
(CXCL)1
214.63 26.11 [7.00; 123.68] 1.74 22.90 [1.50; 77.35] 2.77
CXCL9 5199.74 1087.58 [2.00; 6951.33] 0.75 1683.49 [2.00; 38365.63]
CXCL10 4301.79 675.40 [22.07; 14148.17] 0.30 508.88 [16.86; 14685.22]
Basic fibroblast
growth factor (FGF
basic)
18.02 15.74 [0.67; 73.25] 8.96 [0.56; 283.31]
Granulocyte-colony
stimulating factor
(G-CSF)
36.41 25.33 [8.85; 235.96] 24.20 [0.87; 2358.95]
Granulocyte-
macrophage
colony-stimulating
factor (GM-CSF)
16.73 11.42 [1.20; 85.95] 5.04 [0.21;704.31]
Leukemia
inhibitory factor
(LIF)
17.89 11.00 [1.20; 15.73] 1.14 5.28 [0.32; 144.47] 0.12
Macrophage
colony-stimulating
factor (M-CSF)
41.56 7.00 [0.68; 9.6] 4.33 5.69 [0.31; 32.25] 1.29
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Table 5. Cont.
Analyte Fatal
(pg/mL)
Late HFRS Early HFRS
pg/mL Fold Change pg/mL FoldChange
Macrophage
migration
inhibitory factor
(MIF)
274.66 111.42 [0.42; 1440.27] 162.41 [6.00; 1951.05]
Hepatocyte growth
factor (HGF) 1153.94 40.45 [1.59; 707.00] 1.63 109.26 [3.23; 4732.69] 0.24
Nerve growth
factor b-(NGF) 7.32 4.00 [0.72; 5.10] 1.44 4.00 [0.32; 16.44] 0.45
Stem cell factor
(SCF) 186.95 38.60 [7.00; 95.30] 1.96 48.99 [7.00; 566.30] 0.33
SCGF-b 115197.14 4131.02 [39.00;14076.65] 8.18
5740.14 [39.00;
50992.29] 2.26
TNF-β 54.64 0.31 [0.09; 5.00] 10.93 0.40 [0.14; 3.00] 18.21
Tumor necrosis
factor related
apoptosis-inducing
ligand (TRAIL)
42.91 12.12 [0.24; 225.08] 27.54 [0.46; 225.08]
Tumor necrosis
factor (TNF)-α 14.39 35.91 [2.23; 194.11] 23.63 [1.44; 2117.67]
Platelet-derived
growth factor
(PDGF)-bb
129.28 267.95 [32.09; 3903.78] 414.96 [3.00; 4291.09]
Vascular
endothelial growth
factor (VEGF)
20.38 99.26 [1.72; 1822.04] 67.12 [1.27; 1822.04]
Statistical analyses were conducted using R language for statistical computing [11], RStudio [12,13] and package
“tableone” [9]. Continuous variables were presented with their respective median (M), first (Q1) and third
(Q3) quartiles. Categorical variables were presented with cross-tables. Comparisons were carried out using
Mann–Whitney test for continuous and Fisher’s exact test for categorical variables. The threshold used for statistical
significance was p < 0.05. Red – significantly increased; Blue – significantly decreased.
The level of the majority of cytokines was within the range detected in the early and late HFRS sera.
However, levels of several cytokines (IL-7, IL-18, CCL5, SCGF-b and TNF-β) differed between fatal
and non-fatal HFRS. The level of IL-7 was at the lowest in the early non-fatal HFRS. When compared
to non-fatal late HFRS, level of IL-7 was 11.65 times lower in the fatal HFRS case. Fatal case serum was
collected on day 7 of the disease, which is close to the average time of serum collection in the late stage
HFRS patients (10.5 ± 0.8 days). Therefore, it could be expected that IL-7 levels should be increasing in
the fatal HFRS. Instead, the interleukin levels remained low, suggesting a deficiency in IL-7 pathways.
IL-7 is produced by the thymus, bone marrow and lymph node stroma cells [19,20]. The absence of IL-7
signaling is responsible for a failure to develop γδT cells and NK-T cells [21,22], which are essential for
anti-viral protection [23,24]. Also, IL-7 promotes survival of NK cells by inhibiting their apoptosis [25].
Interestingly, activation and proliferation of NK cells has been demonstrated in HFRS and HPS [26,27],
strongly indicating the role of these leukocytes in pathogenesis of hantavirus infection. Our data
further support the importance of NK in HFRS pathogenesis, and more so a potential protective role of
these cells.
In contrast to IL-7, levels of IL-18, CCL5, SCGF-b and TNF-β were very much higher in the fatal
cases serum as compared to early and late HFRS cases. These cytokines have pleiotropic effects linked
to stem cell proliferation, mononuclear leukocyte chemotaxis and inflammation; however, one shared
feature is that these cytokines target mononuclear leukocytes. SCGF-b triggers proliferative activity of
hematopoietic progenitor cells [28] and, together with Flt-3 Ligand and VEGF, it can promote the CD34
+ CD133+ progenitors expansion and differentiation into the endothelial cells [29,30]. TNF-β plays a
central role in establishing lymphoid microenvironments, host defense and inflammation. Just like
SCGF-b, TNF-βhas been implicated in pathogenesis of inflammation [31,32]. One way TNF-β is thought
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to contribute to inflammation by inducing the secretion of CCL5 [33]. CCL5 is thought to contribute to
inflammation by increasing chemotaxis of activated mononuclear leukocytes [34–36]. Transendothelial
migration of leukocytes is regulated by interaction between CCL5 and its receptor CCR5 [37], where the
expression of the wild type CCR5 receptor is essential for the effective chemotaxis [38,39]. Interestingly,
the wild type CCR5 genotype was identified in the fatal HFRS case, suggesting the most effective
interaction between the ligand (CCL5) and the receptor.
The role of inflammation in pathogenesis of fatal HFRS is supported by finding a high level of IL-18
in the serum of the fatal case. IL-18 has been linked to a severe inflammation [40] and was suggested
as a predictor for a severe outcome [41,42] in inflammatory diseases. We have previously shown
the importance of IL-18 in pathogenesis of fatal hantavirus infections [27], where increased cytokine
levels were detected in fatal hantavirus pulmonary syndrome (HPS) cases. IL-18 could contribute to
inflammation by upregulation of vascular cell adhesion molecule-1 (VCAM-1) and E-selectin expression
in endothelial cells [43]. In addition to inflammation and leukocyte chemotaxis, IL-18 together with
IL-15 and IL-12 induces a Th1 immune response [44]. Therefore, it could be suggested that the massive
migration of mononuclear leukocytes contributes to pathogenesis of the fatal HFRS.
Massive failure of blood tissue barriers was evident in this fatal HFRS case as bleeding and
ascites were continuously reported in this patient. The involvement of the gastro-intestinal tract (GIT),
especially in having a compromised blood-tissue barrier at the earliest stages of the disease, was
supported by the clinical finding of “coffee grounds” vomiting and GI bleeding.
3.3. Local Hantavirus Epidemiology
Lung samples from seven small rodents captured around Vasilievo village were collected and used
for RNA extraction. Two out of seven (28.6%) bank voles were positive for PUUV RNA, which was
later identified as RUS genetic lineage (strain PUUV/Vasilevo/MG_130/2015; Figure 3). Interestingly,
the PUUV from fatal HFRS was identified as FIN genetic lineage (Figure 3), which has been previously
found in non-fatal HFRS cases from Republic of Tatarstan [45]). Therefore, we suggest that the fatal
outcome in this HFRS case could be related to the hosts’ reaction to infection rather than the viral
strain. PUUV strains containing the S-segment of the RUS and FIN lineages were also found in the
bank vole populations in the areas adjacent to Vasilievo. Some of these strains were included into the
phylogenetic analysis in this study (Figure 3). The nucleotide sequence of these strains was 98%–100%
identity to the sequences detected in the non-fatal HFRS patients. Thus, similar PUUV strains were
identified in captured bank voles and in HFRS patients.
4. Conclusions
PUUV remains an emergent infection in Republic of Tatarstan, Russia. HFRS is an acute zoonotic
infection that is caused by PUUV. The HFRS incidence rate in Republic of Tatarstan is one of the
highest in Russia, with over 1000 cases being registered annually [1,46]. The disease is normally mild,
with complete recovery of the majority of patients. However, fatal HFRS have been documented
during some outbreaks, with a mortality rate of 0.43% [1]. Cytokine storm and excessive immune
response have been suggested to play a central role in pathogenesis of hantavirus infection [47–50].
Our data further confirms this hypothesis, where increased cytokine and chemokine production was
demonstrated in this fatal HFRS case as compared to non-fatal cases. It should be noted that the level
of IL-18 was significantly higher in fatal HFRS than in non-fatal. This cytokine was implicated into
pathogenesis of the severe form of the disease and fatal outcomes of cardiovascular diseases, sepsis,
allergic reactions, and ulcerative colitis [41,44,51–53]. Also, we have shown that IL-18 was significantly
upregulated in fatal HPS cases [27]. Therefore, we propose that IL-18 is important for pathogenesis of
cytokine storm, with high likelihood of a fatal outcome in an HFRS case.
We propose that differences in a patient’s humoral immune response to the virus could be a
contributing factor in fatal HFRS. Differences in epitope recognition by antibodies from patients with
different outcomes of the disease are reported regularly [54–56]. It has been suggested that changes
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in epitope recognition could lead to inability of antibodies to interfere with virus replication [1,54].
In the present HFRS case, changes in the epitope recognition were associated with a low neutralizing
antibody titer, which could contribute to pathogenesis and the fatal outcome.
Taken together, our data confirms the cytokine storm hypothesis of hantavirus pathogenesis,
presenting IL-18 as its potential leading force. Significant changes in hantavirus epitope recognition
and weak neutralizing antibody production could also contribute to failure of immune protection
against PUUV. Cytokine driven leukocyte infiltration, including CTL, could cause a detrimental effect
on tissue structure, thereby promoting vascular leakage and further contributing to pathology in HFRS.
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